Access to acquire MacroChem
This article was originally published in Scrip
Executive Summary
Access Pharmaceuticals, which is focused on developing and commercialising cancer products, is to acquire fellow US firm MacroChem in a deal valued at around $9 million. MacroChem's portfolio includes two early clinical-stage oncology products that it acquired when it bought Virium Pharmaceuticals earlier this year.